A Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen-Targeted Oncolytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate Cancer

Eric J. Small, Michael A. Carducci, James M. Burke, Ronald Rodriguez, Lawrence Fong, Lynn van Ummersen, D. C. Yu, Junko Aimi, Dale Ando, Peter Working, David Kirn, George Wilding

Research output: Contribution to journalArticle

168 Citations (Scopus)

Abstract

CG7870 is a replication-selective oncolytic adenovirus genetically engineered to replicate preferentially in prostate tissue. In a previous phase I/II clinical trial of intraprostatic delivery of CG7870 for locally recurrent prostate cancer this virus was well tolerated. In this phase I study CG7870 was administered as a single intravenous infusion in a group-sequential dose escalation design (1 × 1010 to 6 × 1012 viral particles (vp)) to 23 patients with hormone-refractory metastatic prostate cancer. Flulike symptoms (fever, fatigue, rigors, nausea, and/or vomiting) were the most common adverse events. Three therapy-related grade 3 adverse events were reported, one of which (fatigue) was serious. At doses greater than 1012 vp all five patients experienced asymptomatic grade 1 to 2 transaminitis and/or isolated d-dimer elevations starting on day 2 through 8; dose escalation was therefore halted at 6 × 1012 vp. All tested patients had CG7870 genomes present in the peripheral blood for at least 90 minutes after infusion; patients in the highest dose group had persistence of genomes through 29 days. A "secondary" or "delayed" peak in plasma CG7870 genome copies (defined as a >10-fold increase in CG7870 genomes from nadir concentration) suggestive of active viral replication and shedding into the bloodstream was detected in 16/23 (70%) patients. CG7870 was detected in the saliva of 3 patients, whereas all urine samples tested negative. All patients developed antibodies to CG7870. Dose-related increases in interleukins 6 and 10 (IL-6, IL-10) blood levels were detected. The peak IL-6 concentration after CG7870 treatment was associated with a transient, asymptomatic decrease in blood pressure. No partial or complete prostate-specific antigen (PSA) responses were observed; however, 5 patients had a decrease in serum PSA of 25% to 49% following a single treatment, including 3 of 8 patients at the highest dose levels.

Original languageEnglish (US)
Pages (from-to)107-117
Number of pages11
JournalMolecular Therapy
Volume14
Issue number1
DOIs
StatePublished - Jul 2006
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Adenoviridae
Prostatic Neoplasms
Hormones
Genome
Virion
Interleukin-6
Therapeutics
Interleukin-10
Fatigue
Virus Shedding
Phase II Clinical Trials
Clinical Trials, Phase I
Saliva
Intravenous Infusions
Nausea
Vomiting
Prostate
Fever
Urine

Keywords

  • adenovirus
  • gene therapy
  • hormone refractory
  • prostate cancer
  • replication competent

ASJC Scopus subject areas

  • Molecular Biology

Cite this

A Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen-Targeted Oncolytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate Cancer. / Small, Eric J.; Carducci, Michael A.; Burke, James M.; Rodriguez, Ronald; Fong, Lawrence; van Ummersen, Lynn; Yu, D. C.; Aimi, Junko; Ando, Dale; Working, Peter; Kirn, David; Wilding, George.

In: Molecular Therapy, Vol. 14, No. 1, 07.2006, p. 107-117.

Research output: Contribution to journalArticle

Small, Eric J. ; Carducci, Michael A. ; Burke, James M. ; Rodriguez, Ronald ; Fong, Lawrence ; van Ummersen, Lynn ; Yu, D. C. ; Aimi, Junko ; Ando, Dale ; Working, Peter ; Kirn, David ; Wilding, George. / A Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen-Targeted Oncolytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate Cancer. In: Molecular Therapy. 2006 ; Vol. 14, No. 1. pp. 107-117.
@article{8216648fbbe14a16916a201bc8a319f5,
title = "A Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen-Targeted Oncolytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate Cancer",
abstract = "CG7870 is a replication-selective oncolytic adenovirus genetically engineered to replicate preferentially in prostate tissue. In a previous phase I/II clinical trial of intraprostatic delivery of CG7870 for locally recurrent prostate cancer this virus was well tolerated. In this phase I study CG7870 was administered as a single intravenous infusion in a group-sequential dose escalation design (1 × 1010 to 6 × 1012 viral particles (vp)) to 23 patients with hormone-refractory metastatic prostate cancer. Flulike symptoms (fever, fatigue, rigors, nausea, and/or vomiting) were the most common adverse events. Three therapy-related grade 3 adverse events were reported, one of which (fatigue) was serious. At doses greater than 1012 vp all five patients experienced asymptomatic grade 1 to 2 transaminitis and/or isolated d-dimer elevations starting on day 2 through 8; dose escalation was therefore halted at 6 × 1012 vp. All tested patients had CG7870 genomes present in the peripheral blood for at least 90 minutes after infusion; patients in the highest dose group had persistence of genomes through 29 days. A {"}secondary{"} or {"}delayed{"} peak in plasma CG7870 genome copies (defined as a >10-fold increase in CG7870 genomes from nadir concentration) suggestive of active viral replication and shedding into the bloodstream was detected in 16/23 (70{\%}) patients. CG7870 was detected in the saliva of 3 patients, whereas all urine samples tested negative. All patients developed antibodies to CG7870. Dose-related increases in interleukins 6 and 10 (IL-6, IL-10) blood levels were detected. The peak IL-6 concentration after CG7870 treatment was associated with a transient, asymptomatic decrease in blood pressure. No partial or complete prostate-specific antigen (PSA) responses were observed; however, 5 patients had a decrease in serum PSA of 25{\%} to 49{\%} following a single treatment, including 3 of 8 patients at the highest dose levels.",
keywords = "adenovirus, gene therapy, hormone refractory, prostate cancer, replication competent",
author = "Small, {Eric J.} and Carducci, {Michael A.} and Burke, {James M.} and Ronald Rodriguez and Lawrence Fong and {van Ummersen}, Lynn and Yu, {D. C.} and Junko Aimi and Dale Ando and Peter Working and David Kirn and George Wilding",
year = "2006",
month = "7",
doi = "10.1016/j.ymthe.2006.02.011",
language = "English (US)",
volume = "14",
pages = "107--117",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - A Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen-Targeted Oncolytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate Cancer

AU - Small, Eric J.

AU - Carducci, Michael A.

AU - Burke, James M.

AU - Rodriguez, Ronald

AU - Fong, Lawrence

AU - van Ummersen, Lynn

AU - Yu, D. C.

AU - Aimi, Junko

AU - Ando, Dale

AU - Working, Peter

AU - Kirn, David

AU - Wilding, George

PY - 2006/7

Y1 - 2006/7

N2 - CG7870 is a replication-selective oncolytic adenovirus genetically engineered to replicate preferentially in prostate tissue. In a previous phase I/II clinical trial of intraprostatic delivery of CG7870 for locally recurrent prostate cancer this virus was well tolerated. In this phase I study CG7870 was administered as a single intravenous infusion in a group-sequential dose escalation design (1 × 1010 to 6 × 1012 viral particles (vp)) to 23 patients with hormone-refractory metastatic prostate cancer. Flulike symptoms (fever, fatigue, rigors, nausea, and/or vomiting) were the most common adverse events. Three therapy-related grade 3 adverse events were reported, one of which (fatigue) was serious. At doses greater than 1012 vp all five patients experienced asymptomatic grade 1 to 2 transaminitis and/or isolated d-dimer elevations starting on day 2 through 8; dose escalation was therefore halted at 6 × 1012 vp. All tested patients had CG7870 genomes present in the peripheral blood for at least 90 minutes after infusion; patients in the highest dose group had persistence of genomes through 29 days. A "secondary" or "delayed" peak in plasma CG7870 genome copies (defined as a >10-fold increase in CG7870 genomes from nadir concentration) suggestive of active viral replication and shedding into the bloodstream was detected in 16/23 (70%) patients. CG7870 was detected in the saliva of 3 patients, whereas all urine samples tested negative. All patients developed antibodies to CG7870. Dose-related increases in interleukins 6 and 10 (IL-6, IL-10) blood levels were detected. The peak IL-6 concentration after CG7870 treatment was associated with a transient, asymptomatic decrease in blood pressure. No partial or complete prostate-specific antigen (PSA) responses were observed; however, 5 patients had a decrease in serum PSA of 25% to 49% following a single treatment, including 3 of 8 patients at the highest dose levels.

AB - CG7870 is a replication-selective oncolytic adenovirus genetically engineered to replicate preferentially in prostate tissue. In a previous phase I/II clinical trial of intraprostatic delivery of CG7870 for locally recurrent prostate cancer this virus was well tolerated. In this phase I study CG7870 was administered as a single intravenous infusion in a group-sequential dose escalation design (1 × 1010 to 6 × 1012 viral particles (vp)) to 23 patients with hormone-refractory metastatic prostate cancer. Flulike symptoms (fever, fatigue, rigors, nausea, and/or vomiting) were the most common adverse events. Three therapy-related grade 3 adverse events were reported, one of which (fatigue) was serious. At doses greater than 1012 vp all five patients experienced asymptomatic grade 1 to 2 transaminitis and/or isolated d-dimer elevations starting on day 2 through 8; dose escalation was therefore halted at 6 × 1012 vp. All tested patients had CG7870 genomes present in the peripheral blood for at least 90 minutes after infusion; patients in the highest dose group had persistence of genomes through 29 days. A "secondary" or "delayed" peak in plasma CG7870 genome copies (defined as a >10-fold increase in CG7870 genomes from nadir concentration) suggestive of active viral replication and shedding into the bloodstream was detected in 16/23 (70%) patients. CG7870 was detected in the saliva of 3 patients, whereas all urine samples tested negative. All patients developed antibodies to CG7870. Dose-related increases in interleukins 6 and 10 (IL-6, IL-10) blood levels were detected. The peak IL-6 concentration after CG7870 treatment was associated with a transient, asymptomatic decrease in blood pressure. No partial or complete prostate-specific antigen (PSA) responses were observed; however, 5 patients had a decrease in serum PSA of 25% to 49% following a single treatment, including 3 of 8 patients at the highest dose levels.

KW - adenovirus

KW - gene therapy

KW - hormone refractory

KW - prostate cancer

KW - replication competent

UR - http://www.scopus.com/inward/record.url?scp=33745161873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745161873&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2006.02.011

DO - 10.1016/j.ymthe.2006.02.011

M3 - Article

C2 - 16690359

AN - SCOPUS:33745161873

VL - 14

SP - 107

EP - 117

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 1

ER -